Does proctosigmoiditis in inflammatory bowel disease presage the imminent onset of symptoms?
This study was undertaken to determine if asymptomatic children and adolescents with inflammatory bowel disease and moderate to severe anorectosigmoid inflammation might remain symptom-free for at least 12 months without specific intrarectal therapy. We prospectively studied 13 asymptomatic patients 6-21 years of age (four with Crohn's disease and nine with nonspecific colitis) with previously documented anorectosigmoid inflammation. Of these 13, four had moderate to severe anorectosigmoid inflammation both endoscopically and histologically. These four patients (two with Crohn's disease and two with nonspecific colitis) were entered into the second phase of the study. Three were receiving sulfasalazine, and one received methylprednisolone, 4 mg/day, and 6-mercaptopurine, 50 mg/day. None received intrarectal therapy. Clinical evaluation revealed that all four remained asymptomatic for 12 months despite the continued presence of moderate to severe anorectosigmoid inflammation. These results indicate that in children and adolescents with inflammatory bowel disease, the presence of inflammation of the anorectosigmoid does not necessarily correlate with or presage the onset of symptoms of proctosigmoiditis. Therefore, active inflammation of the anorectosigmoid is not the sole prerequisite for intrarectal therapy. The clinician should be guided by the symptoms of the patient, not by the presence or absence of active anorectosigmoid inflammation.
Daum
F
F
Department of Pediatrics and Laboratories, North Shore University Hospital, Manhasset, NY 11030.
Markowitz
J
J
Rosa
J
J
Kahn
E
E
Simpser
E
E
Aiges
H
H
D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D003092:Colitis / Q000150:complications*; D003424:Crohn Disease / Q000150:complications* / Q000188:drug therapy; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000150:complications* / Q000188:drug therapy; D015122:Mercaptopurine / Q000627:therapeutic use; D008775:Methylprednisolone / Q000627:therapeutic use; D011350:Proctocolitis / Q000150:complications* / Q000188:drug therapy; D011446:Prospective Studies; D012460:Sulfasalazine / Q000627:therapeutic use
D012460:Sulfasalazine; D015122:Mercaptopurine; D008775:Methylprednisolone